Silver Book Fact

Pioglitazone associated with relative risk reduction in recurrent stroke

The PROactive trial to manage glucose in diabetics with a history of cardiovascular disease, stroke, or other vascular risk factors found that treatment with pioglitazone was associated with a 47% relative risk reduction in recurrent stroke.

Wilcox R, Bousser M, Betteridge J, Scernthaner G, et al. Effects of Pioglitazone in Patients with Type 2 Diabetes with or without Previous Stroke: Results from PROactive (PROspective pioglitAzone Clinical Trial in macro Vascular Events 04). Stroke. 2007; 38(3): 865-73. http://stroke.ahajournals.org/cgi/content/short/38/3/865

Reference

Title
Effects of Pioglitazone in Patients with Type 2 Diabetes with or without Previous Stroke: Results from PROactive (PROspective pioglitAzone Clinical Trial in macro Vascular Events 04)
Publication
Stroke
Publication Date
2007
Authors
Wilcox R, Bousser M, Betteridge J, Scernthaner G, et al
Volume & Issue
Volume 38, Issue 3
Pages
865-73
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • The projected economic value of eliminating deaths from heart disease is approximately $48 trillion.  
  • Survival rates of patients ages 65-75 with valve repair and replacement
     
  • Improvements in QoL from TAVR in SAS patients
    Symptomatic aortic stenosis (SAS) patients who underwent transcatheter aortic valve replacement (TAVR) experienced quality of life (QoL) improvements from 5.3 at baseline (10 point scale with 10=best imaginable health state)…  
  • Pioglitazone associated with relative risk reduction in recurrent stroke
    The PROactive trial to manage glucose in diabetics with a history of cardiovascular disease, stroke, or other vascular risk factors found that treatment with pioglitazone was associated with a 47% relative…  
  • Identifying individuals at high risk for developing AFib
    Using simple bedside measures, identification of individuals at risk for developing atrial fibrillation is feasible. Selecting high-risk individuals for inclusion in atrial fibrillation prevention trials may also enhance prevention strategies.